Publication
EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (11)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 11
- cancerLung Adenocarcinomacivic_curation1.00
- cancerLung Non-Small Cell Carcinomacivic_curation1.00
- cancerMinimally Invasive Lung Adenocarcinomacivic_curation1.00
- drugErlotinibcivic_curation1.00
- drugGefitinibcivic_curation1.00
- geneEGFRcivic_curation1.00
- variantEGFR E746_A750delcivic_curation1.00
- variantEGFR E746_T751>Icivic_curation1.00
- variantEGFR L747_S752delinsQcivic_curation1.00
- variantEGFR L858Rcivic_curation1.00
- variantEGFR Mutationcivic_curation1.00
Curated evidence
Evidence citing this paper (10)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 15329413
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| EGFR E746_T751>I1 | ||||||||
| Gefitinib | Lung Adenocarcinoma | Predictive | C | Supports Sensitivity Response | 2 | accepted | EID4209Mutational profiling was performed on EGFR exons 18-24 from a group of 10 retrospectively chosen lung cancer patients who had shown partial response or clinical imporvement in response to gefitinib. O… (full text at CIViC) PMID 15329413 · Pao et al., 2004 · Open in CIViC | civic |
| EGFR L747_S752delinsQ1 | ||||||||
| Erlotinib | Lung Adenocarcinoma | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID4667EGFR exons 18-24 were analyzed in 7 patients who had shown a partial response to erlotinib in a phase II trial for bronchioloalveolar carcinoma (BAC, or in situ pulmonary adenocarcinoma). One patient … (full text at CIViC) PMID 15329413 · Pao et al., 2004 · Open in CIViC | civic |
| EGFR L858R3 | ||||||||
| Gefitinib | Lung Adenocarcinoma | Predictive | C | Supports Sensitivity Response | 1 | accepted | EID2624Mutational profiling was performed on EGFR exons 18-24 from a group of 10 retrospectively chosen patients who had shown partial response or clinical improvement in response to gefitinib. Of 7 tumors w… (full text at CIViC) PMID 15329413 · Pao et al., 2004 · Open in CIViC | civic |
| (oncogenic) | Lung Non-Small Cell CarcinomaCURATED_BROADER | Oncogenic | B | Supports Oncogenicity | 3 | submitted | EID13027In this study, EGFR L858R was identified in multiple lung non-small cell carcinoma (NSCLC) cohorts, including 1 of 10 gefitinib-sensitive tumors, 3 of 7 erlotinib-sensitive tumors, 5 of 15 untreated … (full text at CIViC) PMID 15329413 · Pao et al., 2004 · Open in CIViC | civic |
| Erlotinib | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | C | Supports Sensitivity Response | 2 | accepted | EID2632In a phase II trial for bronchioloalveolar carcinoma (BAC, or in situ pulmonary adenocarcinoma), EGFR exons 18-24 were analyzed in 7 patients who had shown a partial response to erlotinib. Two patient… (full text at CIViC) PMID 15329413 · Pao et al., 2004 · Open in CIViC | civic |
| EGFR E746_A750del2 | ||||||||
| Gefitinib | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | C | Supports Sensitivity Response | 4 | accepted | EID4198Mutational profiling was performed on EGFR exons 18-24 from a group of 10 retrospectively chosen patients who had shown partial response or clinical improvement in response to gefitinib. Of 7 tumors w… (full text at CIViC) PMID 15329413 · Pao et al., 2004 · Open in CIViC | civic |
| Erlotinib | Minimally Invasive Lung AdenocarcinomaALIAS | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID2513EGFR exons 18-24 were analyzed in 7 patients who had shown a partial response to erlotinib in a phase II trial for bronchioloalveolar carcinoma (BAC, or in situ pulmonary adenocarcinoma). One patient … (full text at CIViC) PMID 15329413 · Pao et al., 2004 · Open in CIViC | civic |
| EGFR L747_S752del1 | ||||||||
| Gefitinib | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | C | Supports Sensitivity Response | — | submitted | EID2151EGFR exon 19 deletion mutations have been associated with increased sensitivity to first generation EGFR tyrosine kinase inhibitors, including erlotinib and gefitinib. In a Phase 2 clinical trial, lun… (full text at CIViC) PMID 15329413 · Pao et al., 2004 · Open in CIViC | civic |
| EGFR Mutation2 | ||||||||
| Erlotinib | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | B | Supports Sensitivity Response | 3 | accepted | EID3794In a phase II trial for Bronchioloalveolar carcinoma (BAC, or in situ pulmonary adenocarcinoma), EGFR exons 18-24 were analyzed in 7 patients who had shown a partial response to Erlotinib, and 10 pati… (full text at CIViC) PMID 15329413 · Pao et al., 2004 · Open in CIViC | civic |
| Gefitinib | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | B | Supports Sensitivity Response | 3 | accepted | EID2559Mutational profiling was performed on EGFR exons 18-24 from a group of 10 retrospectively chosen patients who had shown partial response or clinical imporvement in response to gefitinib, and in 8 pati… (full text at CIViC) PMID 15329413 · Pao et al., 2004 · Open in CIViC | civic |